Comprehensive History of Mpox Clades: Development, Major Breakthroughs, and Future Predictions
Explore the detailed history of mpox clades, from their discovery and genetic differences to global outbreaks. Learn about key breakthroughs, vaccine developments, and future predictions for managing the virus.
SuZhal
Introduction to Mpox and Its Clades
Mpox, historically known as monkeypox, is a zoonotic viral disease caused by the Monkeypox virus (MPXV), a member of the Orthopoxvirus genus, which also includes the viruses responsible for smallpox and cowpox. The disease was first identified in humans in the 1970s in the Democratic Republic of the Congo (DRC), primarily affecting rural communities in central and western Africa. Over the past few decades, mpox has gained global attention due to sporadic outbreaks and increasing transmission across continents.
The virus is divided into two major clades based on geographic and genetic distinctions: Clade I (formerly called the Congo Basin clade) and Clade II (formerly the West African clade). Within these clades are further subdivisions, with Clade I being broken down into subclades Ia and Ib, and Clade II into IIa and IIb.
While Clade IIb gained prominence in the 2022 global outbreak, Clade Ib has been an emerging concern, particularly in Africa, in 2023 and 2024.
Phases of Development: Clade I and II
Mpox has long been endemic to Africa, but it was only in recent years that international attention grew, largely due to cases spreading outside the continent. The development of these clades occurred over decades, with both sharing genetic similarities but presenting key differences in transmissibility and severity.
-
Early Identifications (1970s - 2000s):
- In 1970, the first human case of mpox was recorded in the DRC. During this time, the disease remained largely confined to central Africa, with sporadic cases in surrounding regions.
- The virus was primarily transmitted through close contact with animals, particularly rodents, and caused small, localized outbreaks.
- Mpox’s genetic diversity began to emerge, leading to the differentiation between Clade I, associated with the Congo Basin region (now broken into Ia and Ib), and Clade II, associated with West Africa.
-
Early 2000s:
- The West African clade (Clade II) was identified in human cases in Nigeria, leading to the understanding of its milder clinical presentation compared to the Congo Basin clade. This helped establish the clades as genetically distinct but related forms of the virus.
-
Clade Ib Outbreaks (2023-2024):
- By 2023, Clade Ib became a focus of international attention due to growing outbreaks in central Africa, particularly in the DRC, where several cases were recorded in mining regions like Kamituga.
- The Africa Centres for Disease Control and Prevention (Africa CDC) declared a public health emergency by mid-2024, with over 500 deaths reported across Africa. The fatality rate of Clade Ib is notably higher, ranging between 3-4%, compared to the less than 1% mortality rate for Clade II
Major Breakthroughs
-
Detection and Differentiation: The discovery of genetic differences between Clade I and Clade II marked a significant milestone. Researchers realized that Clade I, particularly Ib, presented more severe symptoms and had a higher case fatality rate than Clade II. This differentiation was crucial for developing public health responses and informed vaccination strategies.
-
2022 Global Outbreak (Clade IIb): A major breakthrough occurred in 2022 when Clade IIb caused a widespread global outbreak. This was a wake-up call for global health systems, as mpox cases spread beyond Africa, affecting thousands across Europe, North America, and other regions. This outbreak led to a resurgence of interest in smallpox vaccines (which are effective against mpox), as well as new diagnostic and containment strategies.
-
Vaccine and Therapeutics: Vaccines developed for smallpox, such as Imvamune and ACAM2000, have been shown to provide cross-protection against mpox. During the 2022 outbreak, these vaccines were deployed to control the spread, particularly in high-risk populations. The introduction of post-exposure prophylaxis with these vaccines helped reduce the severity and duration of the disease in individuals exposed to mpox.
Current Status and Challenges
As of 2024, Clade Ib continues to cause significant health challenges in Africa. The rapid spread in regions such as the DRC, coupled with limited healthcare infrastructure, has exacerbated the situation. International health agencies, including the World Health Organization (WHO) and Africa CDC, are working to manage the outbreaks, but challenges remain in terms of timely vaccine deployment and public awareness(Wikipedia).
Outside of Africa, Clade II remains the dominant clade in most global mpox cases, with Clade IIb being the primary cause of the 2022-2023 outbreak. However, Clade Ib’s growing presence raises concerns about its potential to spread beyond Africa, particularly given its higher fatality rate.
Future Predictions
-
Global Spread of Clade Ib: While Clade IIb was responsible for the widespread 2022 outbreak, there is increasing concern about Clade Ib’s potential to spread globally. Given its higher fatality rate and emerging presence outside Africa, health experts are monitoring closely to prevent another global outbreak.
-
Vaccine Development and Accessibility: As Clade Ib spreads, there is an urgent need for more targeted vaccines and therapeutics. While smallpox vaccines provide some protection, there is ongoing research into mpox-specific vaccines that could offer greater efficacy and longer-lasting immunity. Ensuring that these vaccines are accessible to regions like Africa, where the virus is endemic, is critical to controlling future outbreaks.
-
Monitoring and Public Health Infrastructure: Improving diagnostic tools and public health infrastructure in Africa is vital to managing the mpox outbreak caused by Clade Ib. Global cooperation and investment in local healthcare systems will be essential in controlling both current and future outbreaks.
-
Awareness and Prevention: Public health campaigns focused on awareness, prevention, and early detection of mpox, particularly in at-risk populations, will play a significant role in containing the spread of the virus. As the virus is zoonotic, preventing animal-to-human transmission through better management of wildlife and domestic animals is also important for long-term control.
Conclusion
The history of mpox and its clades, particularly Clade Ib, underscores the virus's evolving nature and the challenges it poses to global health. From its origins in rural Africa to its spread across continents, mpox remains a disease that requires vigilance, research, and a robust public health response. With emerging subclades like Ib presenting higher fatality risks, ongoing efforts to develop vaccines, strengthen healthcare systems, and increase awareness are essential to managing future outbreaks.
